The inspector calls
September 28, 2005Research and Development
I have become a pharmacovigilance bore within my company, a prophet of doom. It is worse than that, because for …
Astellas launches Flomaxtra XL
September 27, 2005Sales and Marketing
Astellas has launched Flomaxtra XL, a new treatment for the symptoms of BPH or benign prostatic hyperplasia.The condition is the …
Lilly increasing investment in UK R&D
September 23, 2005Research and Development
Lilly has opened a new £26 million UK research facility, a move which underlines its commitment to developing medicines in …
Novartis pipeline promises cardiovascular advances
September 22, 2005Research and Development
Novartis hopes to expand its presence in cardiovascular medicine with the filing next year of two potentially first-in-class products with …
US rejects Pfizer’s injectable Cox-II
September 22, 2005Sales and Marketing
The FDA has denied approval for Pfizer's injectable pain drug Dynastat, delivering a fresh blow to the embattled Cox-II class …
NICE to review guidance on hypertension treatments
September 22, 2005Research and Development
NICE has set up a specialist advisory group to review new data which could lead to thousands of heart patients …
New data gives Seretide upper hand in respiratory battle
September 20, 2005Sales and Marketing
Seretide's domination in the global respiratory market looks set to be bolstered by a new head to head study with …
Biotechs back change to UK pricing system
September 16, 2005The current UK medicines pricing system discriminates against smaller biotech companies, and should be altered to take this into account, …
New NHS leaders in Alzheimer’s research and development
September 15, 2005A new NHS team has been set up to accelerate the development of new medical treatments for neurodegenerative conditions such …
National healthcare debate launched
September 15, 2005The first of four major events aimed at stimulating debate about the future of healthcare in the community has been …
PCTs, points and their progress
September 15, 2005The Quality and Outcomes Framework (QOF) is the cornerstone of the new GMS contract whereby practices achieve payment for achievement …
Handing over the reins of power
September 14, 2005Sales and Marketing
From poetry to patronage, finding a new chief executive for any pharma or biotech company can be a complicated business, …
Dealing with the generic threat
September 14, 2005Sales and Marketing
The looming spectre of generics is one which no pharma company with successful medicines on the market can afford to …
Postcode prescribing down to poor financial management, says report
September 13, 2005Postcode prescribing will only be eradicated if PCTs and NHS Trusts improve their financial management, according to a new report.The …
Connecting with customers
September 13, 2005Sales and Marketing
Great creative executions, those that have the 'wow' factor and stand out from the crowd, require long-term brand strategy and …
Exubera receives FDA vote of confidence
September 9, 2005Research and Development, Sales and Marketing
Exubera, the first inhaled insulin treatment for diabetes, has moved a step closer to US approval following recommendation approval from …
Pfizer and Sanofi battle challenges on patents
September 8, 2005Sales and Marketing
Two blockbuster drugs are facing key patent challenges on both sides of the Atlantic, with the outcome of the cases …
A far stricter code – but more scope for communication too
September 8, 2005Sales and Marketing
A much tighter UK pharmaceutical industry code of practice looks set to be introduced shortly, with a broad range of …
Latest content
FibroFind appoints Lee Borthwick as CEO
